This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Integer Holdings (ITGR) Q4 Earnings and Sales Beat, Margins Up
by Zacks Equity Research
Integer Holdings (ITGR) reports fourth-quarter results, with earnings and revenues beating their respective consensus marks.
PacBio (PACB) Q4 Earnings Beat, Adjusted Gross Margin Down
by Zacks Equity Research
PacBio (PACB) witnesses strong revenue growth in the fourth quarter, partly aided by customers' continued product transition to the Revio system.
AMN Healthcare (AMN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) dismal results in the majority of its segments led to a soft overall fourth-quarter performance.
ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 (Revised)
by Zacks Equity Research
ResMed's (RMD) new AirCurve11 series incorporates MyAir and AirView digital health apps to provide maximum comfort and support during therapy.
Shockwave Medical (SWAV) Q4 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.
Bio-Rad (BIO) Q4 Earnings Beat, Revenues Miss, Margins Down
by Zacks Equity Research
Bio-Rad (BIO) continues to experience weak demand for Life Science products in China.
Here's Why You Should Retain Insulet (PODD) Stock for Now
by Zacks Equity Research
The huge success of Omnipod 5 boosts investors' confidence in Insulet (PODD).
West Pharmaceutical (WST) Beats on Q4 Earnings, HVP Drives Sales
by Zacks Equity Research
West Pharmaceutical's (WST) fourth-quarter results reflect a strong demand for non-COVID-19 products, especially HVP devices.
Labcorp (LH) Q4 Earnings and Revenues Beat, Margins Fall
by Zacks Equity Research
Strength in Diagnostics Laboratories and Biopharma Laboratory Services businesses contributes to Labcorp's (LH) Q4 performance.
Here's Why You Should Retain IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) growth in CAG business and strong global performance
Avantor (AVTR) Q4 Earnings & Revenues Top Estimates, Margins Down
by Zacks Equity Research
Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft fourth-quarter performance.
Quest Diagnostics (DGX) Boosts Oncology Portfolio With New Test
by Zacks Equity Research
Quest Diagnostics (DGX) debuts the MelaNodal Predict test in collaboration with SkylineDx.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) on its strong segmental performance and impressive restructuring plan.
Bruker (BRKR) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Strength in BioSpin and CALID groups contributes to Bruker's (BRKR) Q4 revenues.
Charles River (CRL) Q4 Earnings Surpass, Margins Contract
by Zacks Equity Research
Charles River (CRL) delivers better-than-expected revenues and earnings in the fourth quarter of 2023.
DaVita (DVA) Q4 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
DaVita's (DVA) robust segmental revenues drive its fourth-quarter performance.
Ecolab (ECL) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performance across the majority of its segments drives its fourth-quarter sales despite business challenges.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Charles River's (CRL) share price is likely to grow, backed by the strength of the RMS segment.
Quest Diagnostics (DGX) Debuts PFAS Blood Test Offering
by Zacks Equity Research
Quest Diagnostics (DGX) introduces the first consumer-initiated blood test with physician consult on questhealth.com.
Is Cardinal (CAH) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Omnicell (OMCL) Q4 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
Omnicell's (OMCL) fourth-quarter 2023 performance favorably reflects a heightened focus on managing costs.
DexCom (DXCM) Beats on Q4 Earnings, Strong CGM Demand Continues
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Prestige Consumer (PBH) Q3 Earnings Top, Gross Margin Expands
by Zacks Equity Research
Prestige Consumer's (PBH) third-quarter fiscal 2024 results reflect the power of a well-positioned and diversified portfolio.
Illumina (ILMN) Q4 Earnings Surpass Estimates, Margin Down
by Zacks Equity Research
Illumina (ILMN) Q4 revenues increase year over year, driven by NovaSeq X instrument and consumables sales.